Active substancePhospholipidsPhospholipids
Similar drugsTo uncover
  • Antralive®
    capsules inwards 
  • L'esfal
    solution in / in 
    FARMAK, PAO     Ukraine
  • Livenciale
    solution in / in 
    Rowecq Limited     United Kingdom
  • Livolife Forte
    capsules inwards 
    KORAL-MED, CJSC     Russia
  • Phosphontsiale®
    capsules inwards 
  • Phosphontsiale® Mono
    solution in / in 
    Bakter, OOO     Russia
  • Essentiale® H
    solution in / in 
  • Essentiale® Fort H
    capsules inwards 
  • Essential phospholipids
    capsules inwards 
    ATOLL, LLC     Russia
  • Essley forte
    capsules inwards 
    ATOLL, LLC     Russia
  • Essley®
    solution in / in 
  • Dosage form: & nbspcapsules gelatinous soft
    Composition:

    Each soft gelatin capsule contains:

    Active substance: Lecithin 857.15 mg with phosphatidylcholine content (synonym: essential phospholipids) 300.00 mg.

    Capsule shell composition: gelatin 260.76 mg, glycerol 145.56 mg, water purified 40.18 mg, iron dye red oxide 4,03 mg, iron dye oxide black 0.93 mg.

    Description:

    Soft gelatinous oblong capsules of brown color. Contents of capsules: oily liquid from golden yellow to brown. It is acceptable to form a small amount of viscous mass from yellow to brown color on the inside of the capsule shell.

    Pharmacotherapeutic group:Hepatoprotective agent
    ATX: & nbsp

    A.05.C   Combination of drugs for the treatment of diseases of the liver and biliary tract

    Pharmacodynamics:

    Essential phospholipids are the main elements of the structure of the cell membrane and cellular organelles. In diseases of the liver, there is always damage to the membranes of the liver cells and their organelles, which leads to disturbances in the activity of the enzymes and receptor systems associated with them, impairment of the functional activity of the hepatic cells, and a decrease in the ability to regenerate.

    Phospholipids, which are part of Lexum® Forte, correspond in their chemical structure to endogenous phospholipids, but exceed endogenous phospholipids by activity due to the higher content of polyunsaturated (essential) fatty acids in them.

    The incorporation of these high-energy molecules into the damaged parts of the cell membranes of hepatocytes restores the integrity of the hepatic cells, promotes their regeneration. Cis-double bonds of their polyunsaturated fatty acids prevent the parallel arrangement of hydrocarbon chains in the phospholipids of cell membranes,phospholipid structure of the cellular membranes of hepatocytes "loosens up", which causes an increase in their fluidity and elasticity, improves the metabolism. The resulting functional blocks increase the activity of enzymes fixed on the membranes and promote the normal, physiological pathway of the most important metabolic processes.

    The phospholipids included in the Lexum® Forte drug regulate the metabolism of lipoproteins, transferring neutral fats and cholesterol to oxidation sites, mainly by increasing the ability of high-density lipoproteins to bind to cholesterol. Thus, there is a normalizing effect on the metabolism of lipids and proteins; on the detoxification function of the liver; on the restoration and preservation of the cellular structure of the liver and phospholipid-dependent enzyme systems; which ultimately prevents the formation of connective tissue in the liver and promotes the natural recovery of liver cells.

    In the excretion of phospholipids in bile there is a decrease in the lithogenic index and stabilization of bile.

    Pharmacokinetics:

    More than 90% of the ingested phospholipids are absorbed in the small intestine.Most of them are cleaved by phospholipase A to 1-acyl-lysophosphatidylcholine, 50% of which immediately undergoes reverse acetylation to polyunsaturated phosphothidylcholine during the absorption process in the intestinal mucosa. This polyunsaturated phosphatidylcholine with a current of lymph enters the bloodstream and from there, mainly in high-density lipoproteins linked to the liver, enters the liver.

    Studies of pharmacokinetics in humans were conducted using dilanolide-phosphatidylcholine with a radioactive label (3H and 14FROM). The holin part was marked 3H, and the remainder of linoleic acid had as a label 14FROM.

    Maximum concentration 3H is reached 6-24 hours after the administration and is 19.9% ​​of the prescribed dose. The half-life of the choline component is 66 hours. Maximum concentration 14C is reached 4-12 hours after administration and is up to 27.9% of the prescribed dose. The half-life of this component is 32 hours.

    In the stool, 2% of the administered dose is detected 3H and 4.5% of the administered dose 14C, in urine - 6% of 3H and only a minimal amount 14FROM.

    Both isotopes are absorbed more than 90% in the intestine.

    Indications:

    - Hepatitis (acute and chronic),

    - fatty degeneration of the liver of various genesis (diabetes mellitus, chronic infections),

    - toxic hepatitis,

    - alcoholic hepatitis,

    - cirrhosis of the liver,

    - Gestosis,

    - radiation sickness,

    - psoriasis (as a means of auxiliary therapy),

    - a violation of liver function in other somatic diseases,

    - prevention of recurrences of gallstones.

    Contraindications:

    Hypersensitivity, children under 12 years.

    Pregnancy and lactation:

    Possible use in pregnancy if the potential benefit to the mother exceeds the risk to the fetus and the baby.

    Data on application during lactation (breastfeeding) are absent. It is recommended to stop breastfeeding for the period of use of the drug.

    Dosing and Administration:

    Inside for 1 - 2 capsules 2-3 times a day before or during meals. Capsules should be swallowed whole, washed down with a small amount of water. The maximum dose of 6 capsules per day.

    In acute hepatitis treatment lasts 1-3 months, with chronic liver damage, regardless of the causative factors, treatment continues for at least 6 months. The course of treatment, if necessary, can be continued or repeated.

    In psoriasis, 2 capsules are used as a supplementary therapy 3 times a day, the course of treatment is 3 months.

    Side effects:

    Usually well tolerated, incl. with prolonged use.

    In rare cases, unpleasant sensations in the epigastric region, diarrhea, allergic reactions (skin rash), nausea are possible.

    Overdose:

    Currently there are no data on cases of overdose.

    Interaction:

    Drug interaction is not described.

    Form release / dosage:

    Capsules, 300 mg.

    Packaging:

    10 capsules per blister of aluminum / pvc.

    For 1, 3, 5 or 10 blisters in a pack of cardboard with instructions for medical use. The packet is packed in shrink film.

    Storage conditions:

    In a dry, the dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    2 years.

    Do not use the product after the expiration date printed on the package.

    Terms of leave from pharmacies:Without recipe
    Registration number:LP-000068
    Date of registration:06.12.2010 / 12.07.2017
    Expiration Date:Unlimited
    The owner of the registration certificate:KORAL-MED, CJSC KORAL-MED, CJSC Russia
    Manufacturer: & nbsp
    Representation: & nbspKORAL-MED, CJSCKORAL-MED, CJSC
    Information update date: & nbsp28.02.2018
    Illustrated instructions
      Instructions
      Up